Literature DB >> 31002254

Metabolomics and Cytokine Analysis for Identification of Severe Drug-Induced Liver Injury.

Zhongyang Xie1,2, Ermei Chen1,2, Xiaoxi Ouyang1,2, Xiaowei Xu2,3, Shanshan Ma1,2, Feiyang Ji1,2, Daxian Wu1,2, Sainan Zhang1,2, Yalei Zhao1,2, Lanjuan Li1,2.   

Abstract

AIM: To evaluate the levels of metabolites and cytokines in the serum of patients with severe and non-severe idiosyncratic drug-induced liver injury (DILI) and to identify biomarkers of DILI severity.
METHODS: Gas chromatography-mass spectrometry (GC-MS) and ultraperformance liquid chromatography-mass spectrometry (UPLC-MS) based metabolomic approaches were used to evaluate the metabolome of serum samples from 29 DILI patients of severity grade 3 (non-severe), 27 of severity grade 4 (severe), and 36 healthy control (HC). The levels of total keratin-18 (K18), fragment K18, and 27 cytokines were determined by enzyme-linked immunosorbent assay.
RESULTS: The alkaline phosphatase activity ( p = 0.021) and international normalized ratio (INR) ( p < 0.001) differed significantly between the severe and non-severe groups. The severe group had a higher serum fragment K18 level than the non-severe group. A multivariate analysis showed good separation between all pairs of the HC, non-severe, and severe groups. According to the orthogonal partial least-squares-discriminant analysis (OPLS-DA) model, 14 metabolites were selected by GC-MS and 17 by UPLC-MS. Among these metabolites, the levels of 16 were increased and of 15 were decreased in the severe group. A pathway analysis revealed major changes in the primary bile acid biosynthesis and alpha-linolenic acid metabolic pathways. The levels of PDGF-bb, IP-10, IL-1Rα, MIP-1β, and TNF-α differed significantly between the severe and non-severe groups, and the levels of most of the metabolites were negatively correlated with those of these cytokines. An OPLS-DA model that included the detected metabolites and cytokines revealed clear separation of the severe and non-severe groups.
CONCLUSION: We identified 31 metabolites and 5 cytokines related to the severity of idiosyncratic DILI. The primary bile acid biosynthesis and alpha-linolenic acid metabolism pathways were also related to the severity of DILI. A model that incorporated the metabolites and cytokines showed clear separation between patients with severe and non-severe DILI, suggesting that these biomarkers have potential as indicators of DILI severity.

Entities:  

Keywords:  GC−MS; LC−MS; OPLS-DA; biomarkers; cytokines; drug-induced liver injury; keratin-18; metabolomics; multivariate analysis; severity

Mesh:

Substances:

Year:  2019        PMID: 31002254     DOI: 10.1021/acs.jproteome.9b00047

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  10 in total

Review 1.  The Potential Role of Metabolomics in Drug-Induced Liver Injury (DILI) Assessment.

Authors:  Marta Moreno-Torres; Guillermo Quintás; José V Castell
Journal:  Metabolites       Date:  2022-06-19

Review 2.  Challenges and Future of Drug-Induced Liver Injury Research-Laboratory Tests.

Authors:  Sabine Weber; Alexander L Gerbes
Journal:  Int J Mol Sci       Date:  2022-05-27       Impact factor: 6.208

3.  Metabonomics study on the hepatoprotective effect mechanism of polysaccharides from different processed products of Angelica sinensis on layer chickens based on UPLC-Q/TOF-MS/MS, multivariate statistical analysis and conjoint analysis.

Authors:  Fan-Lin Wu; Yong-Hao Hu; Peng Ji; Chen-Chen Li; Jian He
Journal:  Biomed Chromatogr       Date:  2022-04-26       Impact factor: 1.911

4.  Serum Metabolomic Analysis of Chronic Drug-Induced Liver Injury With or Without Cirrhosis.

Authors:  Shuai-Shuai Chen; Ying Huang; Yu-Ming Guo; Shan-Shan Li; Zhuo Shi; Ming Niu; Zheng-Sheng Zou; Xiao-He Xiao; Jia-Bo Wang
Journal:  Front Med (Lausanne)       Date:  2021-03-29

5.  Prediction of Liver Weight Recovery by an Integrated Metabolomics and Machine Learning Approach After 2/3 Partial Hepatectomy.

Authors:  Runbin Sun; Haokai Zhao; Shuzhen Huang; Ran Zhang; Zhenyao Lu; Sijia Li; Guangji Wang; Jiye Aa; Yuan Xie
Journal:  Front Pharmacol       Date:  2021-11-30       Impact factor: 5.810

6.  Elevation of Serum Cytokine Profiles and Liver Metabolomic Normalization in Early Convalescence of COVID-19 Patients.

Authors:  Yan Lou; Xiaoying He; Mingxia Deng; Xingjiang Hu; Xi Yang; Lin Liu; Yunzhen Hu; Lingjuan He; Jiali Wang; Li Zhang; Qingwei Zhao; Xiaoyang Lu; Yunqing Qiu
Journal:  Front Med (Lausanne)       Date:  2021-07-07

7.  Metabolomics profiling of Polygoni Multiflori Radix and Polygoni Multiflori Radix Preparata extracts using UPLC-Q/TOF-MS.

Authors:  Zhaoyan Zhang; Liang Yang; Xiaoyan Huang; Yue Gao
Journal:  Chin Med       Date:  2019-10-26       Impact factor: 5.455

Review 8.  Molecular Biomarkers in Drug-Induced Liver Injury: Challenges and Future Perspectives.

Authors:  Siyu Fu; Dongbo Wu; Wei Jiang; Juan Li; Jiang Long; Chengyao Jia; Taoyou Zhou
Journal:  Front Pharmacol       Date:  2020-01-30       Impact factor: 5.810

9.  Targeted Metabolomics Analysis of Bile Acids in Patients with Idiosyncratic Drug-Induced Liver Injury.

Authors:  Zhongyang Xie; Lingjian Zhang; Ermei Chen; Juan Lu; Lanlan Xiao; Qiuhong Liu; Danhua Zhu; Fen Zhang; Xiaowei Xu; Lanjuan Li
Journal:  Metabolites       Date:  2021-12-08

Review 10.  The application of cytokeratin-18 as a biomarker for drug-induced liver injury.

Authors:  Samantha Korver; Joanne Bowen; Kara Pearson; Raymond J Gonzalez; Neil French; Kevin Park; Rosalind Jenkins; Christopher Goldring
Journal:  Arch Toxicol       Date:  2021-07-29       Impact factor: 5.153

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.